Abstract
Applicability of derivative spectrophotometry for the determination of valsartan in the presence of a substance from the group of statins was checked. The obtained results indicate that the proposed method may be effective by using appropriate derivatives: for valsartan and fluvastatin - D1, D2 and D3, for valsartan and pravastatin - D1 and D3, for valsartan and atorvastatin - D2 and D3. The method was characterized by high sensitivity and accuracy. Linearity was maintained in the following ranges: 9.28-32.48 mg mL-1 for valsartan, 8.16-28.56 mg mL-1 f or fluvastatin, 14.40-39.90 mg mL-1 for atorvastatin and 9.60-48.00 mg mL-1 for pravastatin. Determination coefficients were in the range of 0.989-0.999 depending on the analyte and the order of derivative. The precision of the method was high with RSD from 0.1 to 2.5 % and recovery of individual components was within the range of 100 ± 5 %. The developed method was successfully applied to the determination of valsartan combined with fluvastatin, atorvastatin and pravastatin in laboratory prepared mixtures and in pharmaceutical preparations.
References
1. M. Lunder, M. Janić, B. Jug and M. Šabovič, The effects of low-dose fluvastatin and valsartan combination on arterial function: A randomized clinical trial, Eur. J. Intern. Med. 23 (2012) 261-266; https://doi.org/10.1016/j.ejim.2011.11.011
2. V. Savić, B. Eržen, M. Janić, M. Lunder, M. Boncelj, K. Kanc, A. Janež and M. Šabovič, Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients, Diab. Vasc. Dis. Res. 10 (2013) 420-425; https://doi.org/10.1177/1479164113485102
3. M. Janić, M. Lunder, M. Prezelj and M. Šabovič, A combination of low-dose fluvastatin and valsartan decreases inflammation and oxidative stress in apparently healthy middle-aged males, J. Cardiopulm. Rehabil. Prev. 34 (2014) 208-212; https://doi.org/10.1097/HCR.0000000000000027
4. R. C. Hermida, C. Calvo, D. E. Ayala and J. E. Lopez, OR-6: Administration time-dependent efficacy of valsartan-atorvastatin combination in hyperlipidemic patients with essential hypertension, Am. J. Hypertens. 18 (S4) (2005) 2A; https://doi.org/10.1016/j.amjhyper.2005.03.006
5. S. A. Hussein, H. M. El-Wadood, M. A. Abdallah and A. A. Khorshed, HPTLC with fluorescence densitometry for simultaneous determination of some angiotensin II receptor blockers in tablets and plasma, J. AOAC Int. 98 (2015) 354-360; https://doi.org/10.5740/jaoacint.14-179
6. D. Tsvetkova, D. Obreshkova and S. Ognjanov, Validation of TLC densitometry for simultaneous quality and quantity analysis of angiotensin II receptor antagonist losartan, telmisartan and valsartan, Chim. Pharm. 64 (2011) 39-44.
7. T. Inglot, A. Gumieniczek, L. Komsta and A. Kasinska, LC and principal component analysis in the lipophilicity study of seven angiotensin II-AT1 receptor antagonists (sartans), Chromatographia 68 (2008) 977-983; https://doi.org/10.1365/s10337-008-0801-5
8. J. Golubovic, A. Protic, B. Otasevic and M. Zecevic, Quantitative structure-retention relationships applied to development of liquid chromatography gradient-elution method for the separation of sartans, Talanta 150 (2016) 190-197; https://doi.org/10.1016/j.talanta.2015.12.035
9. K. C. Skai and A. P. Mazureki, Identification and determination of selected angiotensin II receptor antagonist group drugs by HPLC method, Acta Pol. Pharm. Drug Res. 68 (2011) 831-837.
10. S. Hillaert and W. V. den Bossche, Optimization and validation of a capillary zone electrophoretic method for the analysis of several angiotensin-II-receptor antagonists. J. Chromatogr. A 979 (2002) 323-333; https://doi.org/10.1016/S0021-9673(02)01247-5
11. S. Hillaert, T. R. M. De Beer, J. O. De Beer and W. V. den Bossche, Optimization and validation of a micellar electrokinetic chromatographic method for the analysis of several angiotensin-II-receptor antagonists, J. Chromatogr. A 984 (2003) 135-146; https://doi.org/10.1016/S0021-9673(02)01832-0
12. S. Zargar and T. A. Wani, New UPLC-MS/MS method for simultaneous determination of telmisartan and hydrochlorthiazide in human plasma, Lat. Am. J. Pharm. 33 (2014) 432-440.
13. E. Şatana, S. Altinay, N. G. Göger, S. A. Özkan and Z. Şentürk, Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC, J. Pharm. Biomed. Anal. 25 (2001) 1009-1013; https://doi.org/10.1016/S0731-7085(01)00394-6
14. M. M. Deshpande, M. P. Mahajan and S. D. Sawant, Simultaneous estimation of valsartan and hydrochlorothiazide in fixed dose combination in UV spectrophotometry, Int. J. Pharm. Sci. Res. 3 (2012) 236-240.
15. T. A. Wani, A. Ahmad, S. Zargar, N. Y. Khalil and I. A. Darwish, Use of response surface methodology for development of new microwell-based spectrophotometric method for determination of atorvastatin calcium in tablets, Chem. Cent. J. 6 (2012) 134-142; https://doi.org/10.1186/1752-153X-6-134
16. I. Muszalska, A. Sobczak, A. Dołhaand and A. Jelińska, Analysis of sartans: A review, J. Pharm. Sci. 103 (2014) 2-28; https://doi.org/10.1002/jps.23760
17. M. S. Tahir, A. Adnan and Q. Syed, Chromatographic resolution of angiotensin II receptor antagonists (sartans), J. Chromatogr. B 1027 (2016) 57-63; https://doi.org/10.1016/j.jchromb. 2016.05.023
18. A. Nakashima, C. Saxer, M. Niina, N. Masuda, K. Iwasaki and K. Furukawa, Determination of fluvastatin and its five metabolites in human plasma using simple gradient reversed-phase highperformance liquid chromatography with ultra-violet detection, J. Chromatogr. B 760 (2001) 17-25; https://doi.org/10.1016/S0378-4347(01)00250-X
19. F. P. Gomes, P. L. Garcia, J. M. P. Alves, A. K. Singh, E. R. M. Kedor-Hackmann and M. I. R. M. Santoro, Development and validation of stability-indicating HPLC methods for quantitative determination of pravastatin, fluvastatin, atorvastatin and rosuvastatin in pharmaceuticals, Anal. Lett. 42 (2009) 1784-1804; https://doi.org/10.1080/00032710903060669
20. E. Kublin, E. Malanowicz, B. Kaczmarska-Graczyk, K. Czerwińska, E. Wyszomirska and A. P. Mazurek, Development of chromatographic method for determination of drugs reducing cholesterol level - statins and ezetimibe, Acta Pol. Pharm. Drug Res. 72 (2015) 429-437.
21. J. L. Yan, Determination of fluvastatin sodium by differential pulse voltammetry, Pak. J. Biol. Sci. 9 (2006) 2156-2158.
22. M. P. S. Neves, P. A. Nouws and C. Delerue-Matos, Direct electroanalytical determination of fluvastatin in a pharmaceutical dosage form: Batch and flow analysis, Anal. Lett. 41 (2008) 2794-2804; https://doi.org/10.1080/00032710802421889
23. G. Ergin, S. Çağlar, A. Önal and S. E. Toker, Spectrophotometric determination of 3-hydroxy-3- methylglutaryl coenzyme-A reductase inhibitors in pharmaceutical preparations, Turk. J. Chem. 37 (2013) 171-181.
24. K. Pasha, S. Muzeeb, S. J. S. Basha, D. Shashikumar, R. Mullangi and N. R. Srinivas, Analysis of five HMG-CoA reductase inhibitors - atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies, Biomed. Chromatogr. 20 (2006) 282-293; https://doi.org/10.1002/bmc.561
25. S. Ertürk, A. Önal and S. M. Çetin, Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples, J. Chromatogr. B. 793 (2003) 193-205; https://doi.org/10.1016/S1570-0232(03)00314-3
26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, Geneva November 2005; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access date April 22, 2017.
27. Polish Pharmacopoeia, Xth ed., Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warszawa 2016.
